Macrophage miRNAs in atherosclerosis

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1861, Issue 12, 2016, Pages 2087-2093

  Karunakaran, Denuja ^a   Rayner, Katey J ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Atherosclerosis; Cholesterol efflux; Inflammation; Macrophage; MicroRNA; Therapeutic

Indexed keywords

ABC TRANSPORTER; MICRORNA;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOGENESIS; CELL SUBPOPULATION; CHOLESTEROL TRANSPORT; HOMEOSTASIS; HUMAN; INFLAMMATION; MACROPHAGE; PRIORITY JOURNAL; ANIMAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; LIPID METABOLISM; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; LIPID METABOLISM; MACROPHAGES; MICRORNAS;

EID: 84959472147     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2016.02.006     Document Type: Article

References (100)

1. [1] Esteller, M., Non-coding RNAs in human disease. Nat. Rev. Genet. 12 (2011), 861–874.
2. [2] Ameres, S.L., Zamore, P.D., Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol. 14 (2013), 475–488.
3. [3] Jonas, S., Izaurralde, E., Towards a molecular understanding of microRNA-mediated gene silencing. Nat. Rev. Genet. 16 (2015), 421–433.
4. [4] Pasquinelli, A.E., MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13 (2012), 271–282.
5. [5] Mah, S.M., Buske, C., Humphries, R.K., Kuchenbauer, F., miRNA*: a passenger stranded in RNA-induced silencing complex?. Crit. Rev. Eukaryot. Gene Expr. 20 (2010), 141–148.
6. [6] Moore, K.J., Tabas, I., Macrophages in the pathogenesis of atherosclerosis. Cell 145 (2011), 341–355.
7. [7] Rader, D.J., Tall, A.R., The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis?. Nat. Med. 18 (2012), 1344–1346.
8. [8] Ramírez, C.M., Rotllan, N., Vlassov, A.V., Dávalos, A., Li, M., Goedeke, L., Aranda, J.F., Cirera-Salinas, D., Araldi, E., Salerno, A., Wanschel, A., Zavadil, J., Castrillo, A., Kim, J., Suárez, Y., Fernández-Hernando, C., Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ. Res. 112 (2013), 1592–1601.
9. [9] de Aguiar Vallim, T.Q., Tarling, E.J., Kim, T., Civelek, M., Baldán, A., Esau, C., Edwards, P.A., MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ. Res. 112 (2013), 1602–1612.
10. [10] Goedeke, L., Rotllan, N., Canfrán-Duque, A., Aranda, J.F., Ramírez, C.M., Araldi, E., Lin, C.-S., Anderson, N.N., Wagschal, A., de Cabo, R., Horton, J.D., Lasunción, M.A., Näär, A.M., Suárez, Y., Fernández-Hernando, C., MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat. Med. 21 (2015), 1280–1289.
11. [11] Rayner, K.J., Esau, C.C., Hussain, F.N., McDaniel, A.L., Marshall, S.M., van Gils, J.M., Ray, T.D., Sheedy, F.J., Goedeke, L., Liu, X., Khatsenko, O.G., Kaimal, V., Lees, C.J., Fernández-Hernando, C., Fisher, E.A., Temel, R.E., Moore, K.J., Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478 (2011), 404–407.
12. [12] Najafi-Shoushtari, S.H., Kristo, F., Li, Y., Shioda, T., Cohen, D.E., Gerszten, R.E., Näär, A.M., MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328 (2010), 1566–1569.
13. [13] Horie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., Hasegawa, K., Yokode, M., Kimura, T., Kita, T., MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 17321–17326.
14. [14] Marquart, T.J., Allen, R.M., Ory, D.S., Baldán, A., miR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 12228–12232.
15. [15] Kardassis, D., Gafencu, A., Zannis, V.I., Dávalos, A., Regulation of HDL genes: transcriptional, posttranscriptional, and posttranslational. Handb. Exp. Pharmacol. 224 (2015), 113–179.
16. [16] Goedeke, L., Aranda, J.F., Fernández-Hernando, C., microRNA regulation of lipoprotein metabolism. Curr. Opin. Lipidol. 25 (2014), 282–288.
17. [17] Ono, K., Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Kimura, T., MicroRNAs and high-density lipoprotein cholesterol metabolism. Int. Heart J. 56 (2015), 365–371.
18. [18] Rayner, K.J., Moore, K.J., MicroRNA control of high-density lipoprotein metabolism and function. Circ. Res. 114 (2014), 183–192.
19. [19] Ouimet, M., Moore, K.J., A big role for small RNAs in HDL homeostasis. J. Lipid Res. 54 (2013), 1161–1167.
20. [20] Goldstein, J.L., DeBose-Boyd, R.A., Brown, M.S., Protein sensors for membrane sterols. Cell 124 (2006), 35–46.
21. [21] Ye, J., DeBose-Boyd, R.A., Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb. Perspect. Biol., 3, 2011, a004754.
22. [22] Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., Marcel, Y.L., Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab. 13 (2011), 655–667.
23. [23] Rayner, K.J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M.L., Tamehiro, N., Fisher, E.A., Moore, K.J., Fernández-Hernando, C., MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328 (2010), 1570–1573.
24. [24] Fernández-Hernando, C., Moore, K.J., MicroRNA modulation of cholesterol homeostasis. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 2378–2382.
25. [25] Ouimet, M., Ediriweera, H.N., Gundra, U.M., Sheedy, F.J., Ramkhelawon, B., Hutchison, S.B., Rinehold, K., van Solingen, C., Fullerton, M.D., Cecchini, K., Rayner, K.J., Steinberg, G.R., Zamore, P.D., Fisher, E.A., Loke, P., Moore, K.J., MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J. Clin. Invest. 125 (2015), 4334–4348.
26. [26] Rayner, K.J., Sheedy, F.J., Esau, C.C., Hussain, F.N., Temel, R.E., Parathath, S., van Gils, J.M., Rayner, A.J., Chang, A.N., Suárez, Y., Fernández-Hernando, C., Fisher, E.A., Moore, K.J., Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121 (2011), 2921–2931.
27. [27] Rottiers, V., Obad, S., Petri, A., McGarrah, R., Lindholm, M.W., Black, J.C., Sinha, S., Goody, R.J., Lawrence, M.S., de Lemos, A.S., Hansen, H.F., Whittaker, S., Henry, S., Brookes, R., Najafi-Shoushtari, S.H., Chung, R.T., Whetstine, J.R., Gerszten, R.E., Kauppinen, S., Näär, A.M., Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci. Transl. Med., 5, 2013 (212ra162–212ra162).
28. [28] Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., Hasegawa, K., Kume, N., Yokode, M., Kita, T., Kimura, T., Ono, K., MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE −/− mice. J. Am. Heart Assoc., 1, 2012, e003376.
29. [29] Karunakaran, D., Thrush, A.B., Nguyen, M.-A., Richards, L., Geoffrion, M., Singaravelu, R., Ramphos, E., Shangari, P., Ouimet, M., Pezacki, J.P., Moore, K.J., Perisic, L., Maegdefessel, L., Hedin, U., Harper, M.-E., Rayner, K.J., Macrophage mitochondrial energy status regulates cholesterol efflux and is enhanced by anti-miR33 in atherosclerosis. Circ. Res. 117 (2015), 266–278.
30. [30] Marquart, T.J., Wu, J., Lusis, A.J., Baldán, A., Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 455–458.
31. [31] Mandolini, C., Santovito, D., Marcantonio, P., Buttitta, F., Bucci, M., Ucchino, S., Mezzetti, A., Cipollone, F., Identification of microRNAs 758 and 33b as potential modulators of ABCA1 expression in human atherosclerotic plaques. Nutr. Metab. Cardiovasc. Dis. 25 (2015), 202–209.
32. [32] Distel, E., Barrett, T.J., Chung, K., Girgis, N.M., Parathath, S., Essau, C.C., Murphy, A.J., Moore, K.J., Fisher, E.A., miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. Circ. Res. 115 (2014), 759–769.
33. [33] Kim, J., Yoon, H., Horie, T., Burchett, J.M., Restivo, J.L., Rotllan, N., Ramírez, C.M., Verghese, P.B., Ihara, M., Hoe, H.-S., Esau, C., Fernández-Hernando, C., Holtzman, D.M., Cirrito, J.R., Ono, K., Kim, J., MicroRNA-33 regulates apoE lipidation and amyloid-β metabolism in the brain. J. Neurosci. 35 (2015), 14717–14726.
34. [34] Greenow, K., Pearce, N.J., Ramji, D.P., The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 83 (2005), 329–342.
35. [35] Hu, Y.-W., Hu, Y.-R., Zhao, J.-Y., Li, S.-F., Ma, X., Wu, S.-G., Lu, J.-B., Qiu, Y.-R., Sha, Y.-H., Wang, Y.-C., Gao, J.-J., Zheng, L., Wang, Q., An agomir of miR-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting pro-inflammatory cytokine production. PLoS One, 9, 2014, e94997.
36. [36] Sun, D., Zhang, J., Xie, J., Wei, W., Chen, M., Zhao, X., MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett. 586 (2012), 1472–1479.
37. [37] Zhang, M., Wu, J.-F., Chen, W.-J., Tang, S.-L., Mo, Z.-C., Tang, Y.-Y., Li, Y., Wang, J.-L., Liu, X.-Y., Peng, J., Chen, K., He, P.-P., Lv, Y.-C., Ouyang, X.-P., Yao, F., Tang, D.-P., Cayabyab, F.S., Zhang, D.-W., Zheng, X.-L., Tian, G.-P., et al. MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages. Atherosclerosis 234 (2014), 54–64.
38. [38] Ramírez, C.M., Dávalos, A., Goedeke, L., Salerno, A.G., Warrier, N., Cirera-Salinas, D., Suárez, Y., Fernández-Hernando, C., MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 2707–2714.
39. [39] Wagschal, A., Najafi-Shoushtari, S.H., Wang, L., Goedeke, L., Sinha, S., de Lemos, A.S., Black, J.C., Ramírez, C.M., Li, Y., Tewhey, R., Hatoum, I., Shah, N., Lu, Y., Kristo, F., Psychogios, N., Vrbanac, V., Lu, Y.-C., Hla, T., de Cabo, R., Tsang, J.S., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat. Med. 21 (2015), 1290–1297.
40. [40] Meiler, S., Baumer, Y., Toulmin, E., Seng, K., Boisvert, W.A., MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 323–331.
41. [41] Jeong, B.-C., Kang, I.-H., Koh, J.-T., MicroRNA-302a inhibits adipogenesis by suppressing peroxisome proliferator-activated receptor γ expression. FEBS Lett. 588 (2014), 3427–3434.
42. [42] Yvan-Charvet, L., Ranalletta, M., Wang, N., Han, S., Terasaka, N., Li, R., Welch, C., Tall, A.R., Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 117 (2007), 3900–3908.
43. [43] Zhu, X., Owen, J.S., Wilson, M.D., Li, H., Griffiths, G.L., Thomas, M.J., Hiltbold, E.M., Fessler, M.B., Parks, J.S., Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 51 (2010), 3196–3206.
44. [44] Eis, P.S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M.F., Lund, E., Dahlberg, J.E., Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 3627–3632.
45. [45] O'Connell, R.M., Taganov, K.D., Boldin, M.P., Cheng, G., Baltimore, D., MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 1604–1609.
46. [46] Nazari-Jahantigh, M., Wei, Y., Noels, H., Akhtar, S., Zhou, Z., Koenen, R.R., Heyll, K., Gremse, F., Kiessling, F., Grommes, J., Weber, C., Schober, A., MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 122 (2012), 4190–4202.
47. [47] Du, F., Yu, F., Wang, Y., Hui, Y., Carnevale, K., Fu, M., Lu, H., Fan, D., MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 759–767.
48. [48] Tian, F.-J., An, L.-N., Wang, G.-K., Zhu, J.-Q., Li, Q., Zhang, Y.-Y., Zeng, A., Zou, J., Zhu, R.-F., Han, X.-S., Shen, N., Yang, H.-T., Zhao, X.-X., Huang, S., Qin, Y.-W., Jing, Q., Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc. Res. 103 (2014), 100–110.
49. [49] Wei, Y., Nazari-Jahantigh, M., Neth, P., Weber, C., Schober, A., MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 449–454.
50. [50] Raitoharju, E., Lyytikäinen, L.-P., Levula, M., Oksala, N., Mennander, A., Tarkka, M., Klopp, N., Illig, T., Kähönen, M., Karhunen, P.J., Laaksonen, R., Lehtimäki, T., miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 219 (2011), 211–217.
51. [51] Marjo, M., Donners, P.C., Wolfs, I.M.J., Stöger, L.J., van der Vorst, Emiel P.C., Pöttgens, C.C.H., Heymans, S., Schroen, B., Gijbels, M.J.J., de Winther, M.P.J., Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One, 7, 2012, e35877.
52. [52] Wei, Y., Zhu, M., Corbalán-Campos, J., Heyll, K., Weber, C., Schober, A., Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 796–803.
53. [53] Pankratz, F., Bemtgen, X., Zeiser, R., Leonhardt, F., Kreuzaler, S., Hilgendorf, I., Smolka, C., Helbing, T., Hoefer, I., Esser, J.S., Kustermann, M., Moser, M., Bode, C., Grundmann, S., MicroRNA-155 exerts cell-specific antiangiogenic but proarteriogenic effects during adaptive neovascularization. Circulation 131 (2015), 1575–1589.
54. [54] Rayner, K.J., MicroRNA-155 in the heart: the right time at the right place in the right cell. Circulation 131 (2015), 1533–1535.
55. [55] Wei, Y., Nazari-Jahantigh, M., Chan, L., Zhu, M., Heyll, K., Corbalán-Campos, J., Hartmann, P., Thiemann, A., Weber, C., Schober, A., The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 127 (2013), 1609–1619.
56. [56] Zhang, S.H., Reddick, R.L., Piedrahita, J.A., Maeda, N., Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992), 468–471.
57. [57] Plump, A.S., Smith, J.D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J.G., Rubin, E.M., Breslow, J.L., Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992), 343–353.
58. [58] Linton, M.F., Atkinson, J.B., Fazio, S., Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation., 267, 1995, 1034–1037.
59. [59] Mahley, R.W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988), 622–630.
60. [60] Ali, K., Middleton, M., Puré, E., Rader, D.J., Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ. Res. 97 (2005), 922–927.
61. [61] Baitsch, D., Bock, H.H., Engel, T., Telgmann, R., Muller-Tidow, C., Varga, G., Bot, M., Herz, J., Robenek, H., von Eckardstein, A., Nofer, J.R., Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 1160–1168.
62. [62] Li, K., Ching, D., Luk, F.S., Raffai, R.L., Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis. Circ. Res. 117 (2015), e1–e11.
63. [63] Cheng, H.S., Njock, M.-S., Khyzha, N., Dang, L.T., Fish, J.E., Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation. Front. Genet., 5, 2014, 422.
64. [64] Cheng, H.S., Sivachandran, N., Lau, A., Boudreau, E., Zhao, J.L., Baltimore, D., Delgado-Olguin, P., Cybulsky, M.I., Fish, J.E., MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol. Med. 5 (2013), 949–966.
65. [65] Chinetti-Gbaguidi, G., Colin, S., Staels, B., Macrophage subsets in atherosclerosis. Nat. Rev. Cardiol. 12 (2015), 10–17.
66. [66] Peled, M., Fisher, E.A., Dynamic aspects of macrophage polarization during atherosclerosis progression and regression. Front. Immunol., 5, 2014, 579.
67. [67] Stöger, J.L., Gijbels, M.J.J., van der Velden, S., Manca, M., van der Loos, C.M., Biessen, E.A.L., Daemen, M.J.A.P., Lutgens, E., de Winther, M.P.J., Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 225 (2012), 461–468.
68. [68] Khallou-Laschet, J., Varthaman, A., Fornasa, G., Compain, C., Gaston, A.-T., Clement, M., Dussiot, M., Levillain, O., Graff-Dubois, S., Nicoletti, A., Caligiuri, G., Macrophage plasticity in experimental atherosclerosis. PLoS One, 5, 2010, e8852.
69. [69] Graff, J.W., Dickson, A.M., Clay, G., McCaffrey, A.P., Wilson, M.E., Identifying functional microRNAs in macrophages with polarized phenotypes. J. Biol. Chem. 287 (2012), 21816–21825.
70. [70] Wang, D., Yan, X., Xia, M., Yang, Y., Li, D., Li, X., Song, F., Ling, W., Coenzyme Q10 promotes macrophage cholesterol efflux by regulation of the activator protein-1/miR-378/ATP-binding cassette transporter G1-signaling pathway. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 1860–1870.
71. [71] Zhang, N., Lei, J., Lei, H., Ruan, X., Liu, Q., Chen, Y., Huang, W., MicroRNA-101 overexpression by IL-6 and TNF-α inhibits cholesterol efflux by suppressing ATP-binding cassette transporter A1 expression. Exp. Cell Res. 336 (2015), 33–42.
72. [72] Mao, M., Lei, H., Liu, Q., Chen, Y., Zhao, L., Li, Q., Luo, S., Zuo, Z., He, Q., Huang, W., Zhang, N., Zhou, C., Ruan, X.Z., Effects of miR-33a-5P on ABCA1/G1-mediated cholesterol efflux under inflammatory stress in THP-1 macrophages. PLoS One, 9, 2014, e109722.
73. [73] Zhao, G.-J., Mo, Z.-C., Tang, S.-L., Ouyang, X.-P., He, P.-P., Lv, Y.-C., Yao, F., Tan, Y.-L., Xie, W., Shi, J.-F., Wang, Y., Zhang, M., Liu, D., Tang, D.-P., Zheng, X.-L., Tian, G.-P., Tang, C.-K., Chlamydia pneumoniae negatively regulates ABCA1 expression via TLR2-nuclear factor-kappa B and miR-33 pathways in THP-1 macrophage-derived foam cells. Atherosclerosis 235 (2014), 519–525.
74. [74] Barter, P.J., Rye, K.-A., Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence?. Clin. Ther. 37 (2015), 2716–2731.
75. [75] Rohatgi, A., Grundy, S.M., Cholesterol efflux capacity as a therapeutic target: rationale and clinical implications. J. Am. Coll. Cardiol. 66 (2015), 2211–2213.
76. [76] Khera, A.V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M.F., Jafri, K., French, B.C., Phillips, J.A., Mucksavage, M.L., Wilensky, R.L., Mohler, E.R., Rothblat, G.H., Rader, D.J., Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364 (2011), 127–135.
77. [77] Rohatgi, A., de Lemos, J.A., Shaul, P.W., HDL cholesterol efflux capacity and cardiovascular events. N. Engl. J. Med. 372 (2015), 1871–1872.
78. [78] Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., Stoffel, M., Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438 (2005), 685–689.
79. [79] Prakash, T.P., Bhat, B., 2′-Modified oligonucleotides for antisense therapeutics., 7, 2007, 641–649.
80. [80] Stenvang, J., Kauppinen, S., MicroRNAs as targets for antisense-based therapeutics. Expert. Opin. Biol. Ther. 8 (2007), 59–81.
81. [81] Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H.F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E.M., Kauppinen, S., LNA-mediated microRNA silencing in non-human primates. Nature 452 (2008), 896–899.
82. [82] Janssen, H.L.A., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A.J., Patick, A.K., Chen, A., Zhou, Y., Persson, R., King, B.D., Kauppinen, S., Levin, A.A., Hodges, M.R., Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368 (2013), 1685–1694.
83. [83] Haussecker, D., Kay, M.A., miR-122 continues to blaze the trail for microRNA therapeutics. Mol. Ther. 18 (2010), 240–242.
84. [84] Cheng, C.J., Bahal, R., Babar, I.A., Pincus, Z., Barrera, F., Liu, C., Svoronos, A., Braddock, D.T., Glazer, P.M., Engelman, D.M., Saltzman, W.M., Slack, F.J., MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518 (2015), 107–110.
85. [85] Misso, G., Di Martino, M.T., De Rosa, G., Farooqi, A.A., Lombardi, A., Campani, V., Zarone, M.R., Gullà, A., Tagliaferri, P., Tassone, P., Caraglia, M., Mir-34: a new weapon against cancer?. Mol. Ther.–Nucleic Acids, 3, 2014, e194.
86. [86] Nair, J.K., Willoughby, J.L.S., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S., Taneja, N., O'Shea, J., Shaikh, S., Zhang, L., van der Sluis, R.J., Jung, M.E., Akinc, A., Hutabarat, R., Kuchimanchi, S., Fitzgerald, K., et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136 (2014), 16958–16961.
87. [87] Broderick, J.A., Zamore, P.D., MicroRNA therapeutics. Gene Ther. 18 (2011), 1104–1110.
88. [88] Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Nakao, T., Nishiga, M., Usami, S., Izuhara, M., Sowa, N., Yahagi, N., Shimano, H., Matsumura, S., Inoue, K., Marusawa, H., Nakamura, T., Hasegawa, K., Kume, N., Yokode, M., Kita, T., Kimura, T., et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat. Commun., 4, 2013, 2883.
89. [89] Karunakaran, D., Richards, L., Geoffrion, M., Barrette, D., Gotfrit, R.J., Harper, M.-E., Rayner, K.J., Therapeutic inhibition of miR-33 promotes fatty acid oxidation but does not ameliorate metabolic dysfunction in diet-induced obesity. Arterioscler. Thromb. Vasc. Biol., 2015 (ATVBAHA.115.306404).
90. [90] Babar, I.A., Cheng, C.J., Booth, C.J., Liang, X., Weidhaas, J.B., Saltzman, W.M., Slack, F.J., Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E1695–E1704.
91. [91] Kheirolomoom, A., Kim, C.W., Seo, J.W., Kumar, S., Son, D.J., Gagnon, M.K.J., Ingham, E.S., Ferrara, K.W., Jo, H., Multifunctional nanoparticles facilitate molecular targeting and miRNA delivery to inhibit atherosclerosis in apoE −/− mice. ACS Nano 9 (2015), 8885–8897.
92. [92] Kuo, C.H., Leon, L., Chung, E.J., Huang, R.T., Inhibition of atherosclerosis-promoting microRNAs via targeted polyelectrolyte complex micelles. J. Mater. Chem. B 2 (2014), 8142–8153.
93. [93] Cao, W.J., Rosenblat, J.D., Roth, N.C., Kuliszewski, M.A., Matkar, P.N., Rudenko, D., Liao, C., Lee, P.J.H., Leong-Poi, H., Therapeutic angiogenesis by ultrasound-mediated microRNA-126-3p delivery. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 2401–2411.
94. [94] Wang, D., Deuse, T., Stubbendorff, M., Chernogubova, E., Erben, R.G., Eken, S.M., Jin, H., Li, Y., Busch, A., Heeger, C.-H., Behnisch, B., Reichenspurner, H., Robbins, R.C., Spin, J.M., Tsao, P.S., Schrepfer, S., Maegdefessel, L., Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1945–1953.
95. [95] Jazbutyte, V., Thum, T., MicroRNA-21: from cancer to cardiovascular disease., 11, 2010, 926–935.
96. [96] Moore, K.J., Rayner, K.J., Local anti-miR delivery: the latest in the arsenal of drug-eluting stents. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1905–1906.
97. [97] Conde, J., Oliva, N., Atilano, M., Song, H.S., Artzi, N., Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nat. Mater., 2015, 10.1038/nmat4497.
98. [98] Bell, D.A., Hooper, A.J., Burnett, J.R., Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin. Investig. Drugs 20 (2011), 265–272.
99. [99] Vogt, A., Parhofer, K.G., The potential of mipomersen, an apoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. Expert. Opin. Pharmacother. 14 (2013), 691–697.
100. [100] Tsimikas, S., Viney, N.J., Hughes, S.G., Singleton, W., Graham, M.J., Baker, B.F., Burkey, J.L., Yang, Q., Marcovina, S.M., Geary, R.S., Crooke, R.M., Witztum, J.L., Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386 (2015), 1472–1483.